Business Context and Reporting Period
This Form 8-K was filed by EyePoint Pharmaceuticals, Inc. on September 12, 2018. The report addresses a specific corporate event under Item 8.01 (Other Events) regarding executive leadership changes.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is the departure of Leonard Blum, Executive Vice President and General Manager, U.S. His separation from the Company is effective as of September 26, 2018.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies beyond the executive departure.
Key Facts for Investor Verification
- Leonard Blum will cease employment with EyePoint Pharmaceuticals, Inc. effective September 26, 2018.
- Blum held the title of Executive Vice President and General Manager, U.S.
- The report was signed by Nancy Lurker, President and Chief Executive Officer.